Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in moderate to severe atopic dermatitis
NCT03559270Phase 3Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2018
- Primary completion
- Oct 2021
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 3
01
Overview
A Phase 3 trial of baricitinib in atopic dermatitis (AD), sponsored by Eli Lilly and Company. Started Jun 2018; status: terminated.
02
Drugs
baricitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03559270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03559270.